Revised Common Rule Reference Guide
The revised Common Rule introduces new exemptions, refined consent elements, and alters IRB oversight for multisite and minimal-risk research.
IRB
IRB Information for Participants and Patient Advocacy Groups
Advarra’s institutional review board (IRB) strives to protect participant rights and welfare throughout the research process.
Adapting to the Evolving Era of Oncology: Implications and Strategies for Research Institutions
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Reviews FAQ
REVIEWS Frequently Asked Questions Find answers to our most frequently asked ethical review questions here. Can’t find what you need?
Institutional Review Board (IRB) Services for Federal Grants
Simplify federal grant submissions with Advarra’s expert IRB support, offering compliance guidance and oversight for both single and multisite studies.
Institutional Review Board (IRB) Services for International Research
Advarra reviews research in the U.S., Puerto Rico, Canada, and limited minimal risk research outside these regions.
Institutional Review Board (IRB) Services Info Sheet
Advarra’s Institutional Review Board (IRB) offers expert guidance, supporting more than 3,500 institutions, academic medical centers, and site networks.
Canadian Institutional Review Board / Research Ethics Board Services
Leverage Advarra’s expertise in Canada as the only officially recognized IRB/REB, offering extensive site reach and top-notch research ethics services.
Single Institutional Review Board (sIRB) Services Info Sheet
As the research community’s preferred sIRB partner, we help you meet regulatory requirements with efficiency and transparency.
Diversity, Equity, and Inclusion in Clinical Research
Achieving diversity, equity, and inclusion (DEI) in clinical trials is crucial for producing comprehensive and effective medical research benefitting all
Decentralized Clinical Trials Involving Biologics: Unique Challenges
Join this webinar to learn about FDA insights on DCTs and biologics. Dr. Eisenman discusses biosafety, risks, and key considerations for safe trials.
Preparing Your Action Plan for the FDA sIRB Mandate
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.